


Title: COMPOSITIONS AND METHOD FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT/HYPERACTIVITY DISORDER WITH METHYLPHENIDATE

Inventor(s): Juan MANTELLE et al. DOCKET NO.: 041457-0630



Figure 1 Mean (linear) d-MPH plasma profiles in 29 subjects on Day 6 after administering 25cm<sup>2</sup> MTS units every 24 h (MTS) for 16 h or 20 mg oral Ritalin<sup>®</sup> at 7 AM, 11 AM and 3 PM daily (Ritalin<sup>®</sup>).



Title: COMPOSITIONS AND METHOD FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT/HYPERACTIVITY DISORDER WITH METHYLPHENIDATE

Inventor(s): Juan MANTELLE et al.
DOCKET NO.: 041457-0630

PH plasma profiles in 29 subjects on Day 6 after

Figure 2 Mean (linear) *l*-MPH plasma profiles in 29 subjects on Day 6 after administering 25cm<sup>2</sup> MTS units every 24 h (MTS) for 16 h or 20 mg oral Ritalin<sup>®</sup> at 7 AM, 11 AM and 3 PM daily (Ritalin<sup>®</sup>).

